Acoramidis vs Eplontersen
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Transthyretin Amyloidosis with Cardiomyopathy
Shared mechanism: Transthyretin (TTR) · full Transthyretin Amyloidosis with Cardiomyopathy pipeline
Acoramidis · Attruby
Marketed by BridgeBio Pharma and partners
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: September 2027 · NCT07298044 (registry estimate)
No aligned efficacy figure on record for this race.
Eplontersen · Wainua
Marketed by AstraZeneca and partners
NCT04136171 · Phase 3 · completed
This was a large randomized, double-blind, placebo-controlled trial of 1,432 treated patients with a hard clinical primary endpoint, cardiovascular death and recurrent cardiovascular events. Eplontersen did not reduce this endpoint significantly compared with placebo, so the trial is well-designed evidence of no clear benefit rather than strong evidence of a positive effect.
Next expected readout: August 2029 · NCT05667493 (registry estimate)
Reported efficacy
Composite Outcome of Cardiovascular (CV) Mortality and Recurrent CV Clinical Events up to Week 140 (Baseline up to Week 140): CARDIO-TTRansform primary composite: rate ratio 0.89 (95% CI 0.73 to 1.09), P=0.28; no significant reduction. (missed)
Result source: NCT04136171
Results for Transthyretin Amyloidosis with Cardiomyopathy
There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.
Acoramidis: registry results are on file for Transthyretin Amyloidosis with Cardiomyopathy, but their comparison mappings are not yet available.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Acoramidis's landscape · Eplontersen's landscape